医学教育

Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials

作者:Zhipeng Sun1,2, Yubing Zhu1, Jufeng Xia2, Tatsuo Sawakami2, Norihiro Kokudo2, Nengwei Zhang1 来源:医学论坛网 日期:2017-11-15
导读

         Current therapies to treat advanced hepatocellular carcinoma (HCC) are not satisfactory because of the high rate of recurrence after treatment and because of severe complications after surgery. Cancer vaccines have been studied for decades to achieve effe

        Current therapies to treat advanced Hepatocellular carcinoma ((HCC)) are not satisfactory because of the high rate of recurrence after treatment and because of severe complications after surgery. cancer vaccines have been studied for decades to achieve effective, microinvasive,long-lasting anti-tumor action. Cancer vaccines are designed to promote tumorspecific immune responses and increase specific cytotoxic CD8-positive T cells. This review summarizes 16 phase I clinical trials of cancer vaccines against HCC that have been conducted over the past 10 years. According to those trials, the Alpha fetoprotein (AFP),Glypican-3 (GPC3), and Multidrug resistance-associated protein 3 (MRP3) vaccines were well tolerated and safe. Some early clinical trials have shown that vaccination resulted in a large number of T cells activated by a specific tumor-associated antigen in the circulation, but clinical outcomes were not satisfactory. This may be because targets for immunosuppressive agents have yet to be clearly determined in HCC. Therapeutic regimens that combine activative agents and suppressive agents may profoundly improve clinical outcomes for patients with HCC in the future.

阅读原文请见:Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials

分享:

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©医学论坛网 版权所有,未经许可不得复制、转载或镜像 京ICP证120392号 京公网安备11010502031486号

京卫网审[2013]第0193号

互联网药品信息服务资格证书:(京)-经营性-2012-0005

//站内统计 //百度统计 //站长统计
*我要反馈: 姓    名: 邮    箱: